The Effect of Chronic Opioid Use on End-Tidal Concentration of Sevoflurane Necessary to Maintain a Bispectral Index Below 50: A Prospective, Single-Blind Study

Anesth Analg. 2017 Jul;125(1):156-161. doi: 10.1213/ANE.0000000000001791.

Abstract

Background: Opioid analgesics decrease the minimum alveolar concentration of inhalation agents during the acute phase response. However, the effect of chronic opioid exposure on minimum alveolar concentration of inhalation agents remains unknown. This study aimed to determine the concentration of sevoflurane necessary to maintain a bispectral index (BIS) <50 (SEVOBIS50) in patients with chronic opioid use compared with those naïve to opioid use.

Methods: We included chronic opioid users who received a stable dose of oral morphine of at least 60 mg/d according to the morphine equivalent daily dose for at least 4 weeks and opioid-naïve patients. General anesthesia that included thiopental, vecuronium, and sevoflurane in oxygen was administered to all patients. Anesthesia was maintained using predetermined end-tidal sevoflurane concentrations. Fifteen minutes after achieving the determined end-tidal sevoflurane concentration through closed circuit anesthesia, BIS was measured for 1 minute in both groups. SEVOBIS50 was determined using Dixon's up-down method and probit analysis.

Results: Nineteen and 18 patients from the chronic opioid and control groups, respectively, were included in the final analysis. SEVOBIS50values for the chronic opioid and control patients were 0.84 (95% confidence interval, 0.58-1.11) and 1.18 (95% confidence interval, 0.96-1.40), respectively (P = .0346).

Conclusions: Our results suggest that the end-tidal concentration of sevoflurane necessary to maintain a BIS <50 is lower for chronic opioid users than for opioid-naïve patients.

Trial registration: ClinicalTrials.gov NCT02582437.

Publication types

  • Clinical Trial
  • Comparative Study

MeSH terms

  • Administration, Inhalation
  • Administration, Oral
  • Adult
  • Aged
  • Analgesics, Opioid / administration & dosage*
  • Analgesics, Opioid / adverse effects
  • Anesthesia, General / methods*
  • Anesthetics, Inhalation / administration & dosage*
  • Consciousness / drug effects*
  • Consciousness Monitors*
  • Drug Administration Schedule
  • Drug Interactions
  • Female
  • Humans
  • Male
  • Methyl Ethers / administration & dosage*
  • Middle Aged
  • Monitoring, Intraoperative / instrumentation*
  • Morphine / administration & dosage*
  • Morphine / adverse effects
  • Prospective Studies
  • Republic of Korea
  • Sevoflurane
  • Single-Blind Method
  • Time Factors

Substances

  • Analgesics, Opioid
  • Anesthetics, Inhalation
  • Methyl Ethers
  • Sevoflurane
  • Morphine

Associated data

  • ClinicalTrials.gov/NCT02582437